Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
|Articles|December 22, 2022
Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Advertisement
Advertisement
Related to this article
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
European Commission Approves First-Line Dato-DXd for Immunotherapy-Ineligible Metastatic TNBC
3
Dr Galsky on Data Supporting the FDA Approval of Perioperative EV/Pembrolizumab in MIBC
4
Dr Choueiri on Safety Data From the Phase 3 LITESPARK-022 Trial in ccRCC
5